| 谷 俊,荆志强,王 卓,姚君燕,洪 靖.参附注射液联合多西他赛治疗晚期非小细胞肺癌的临床效果观察[J].,2019,19(21):4088-4091 |
| 参附注射液联合多西他赛治疗晚期非小细胞肺癌的临床效果观察 |
| Clinical Effect of Shenfu Injection Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer |
| 投稿时间：2019-03-10 修订日期：2019-03-31 |
| DOI：10.13241/j.cnki.pmb.2019.21.020 |
| 中文关键词: 参附注射液 多西他赛 晚期非小细胞肺癌 效果 |
| 英文关键词: Shenfu injection Docetaxel Advanced non-small cell lung cancer Effect |
| 基金项目:陕西省中医药管理局科研项目(JCPT044) |
|
| 摘要点击次数: 768 |
| 全文下载次数: 507 |
| 中文摘要: |
| 摘要 目的：探讨参附注射液联合多西他赛治疗晚期非小细胞肺癌的临床效果和安全性。方法：选取2016年1月~2019年1月我院收治的晚期非小细胞肺癌患者60例，采用随机数字表法将患者分为两组，每组各30例。对照组患者给予多西他赛注射液进行化疗，观察组在对照组的基础上给予参附注射液，比较两组患者治疗后的临床治疗效果，治疗前后免疫功能相关指标、生活质量评分的变化及不良反应的发生情况。结果：治疗后，观察组疾病控制率为86.67%，对照组为60.00%，观察组显著高于对照组(P＜0.05)；对照组患者治疗后CD3+、CD4+和CD4+/CD8+水平显著下降，CD8+水平显著升高，观察组患者CD3+、CD4+和CD4+/CD8+水平显著升高，CD8+水平显著下降，观察组患者CD3+、CD4+和CD4+/CD8+水平显著高于对照组，CD8+水平显著低于对照组(P＜0.05)；两组治疗后的食欲、疼痛、乏力、呼吸困难、痰中带血、咳嗽评分均较治疗前显著下降，且观察组以上指标均显著低于对照组(P＜0.05)；观察组患者中性粒细胞减少和便秘的发生率均显著低于对照组(P＜0.05)，两组血小板减少、恶心呕吐和神经毒性的发生率比较无统计学差异(P＞0.05)。结论：参附注射液联合多西他赛可显著改善晚期非小细胞肺癌患者的免疫功能和生活质量，提高临床治疗效果，且安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical effect and security of shenfu injection combined with docetaxel in the treatment of advanced non-small cell lung cancer. Methods: 60 patients with non-small cell lung cancer were selected from January 2016 to January 2019 in our hospital and divided into two groups according to the random number table method, 30 cases in each group. Patients in the control group were given docetaxel injection for chemotherapy, and those in the observation group were given shenfu injection on the basis of those in the control group. The clinical effect after treatment, changes in immuno-function related indicators, life quality score before and after treatment and adverse reactions were compared between the two groups. Results: After treatment, the disease control rate was 86.67% in the observation group and 60.00% in the control group, which was significantly higher than that in the control group (P<0.05). After treatment, the levels of CD3+, CD4+ and CD4+ CD8+ in the control group were significantly decreased, and the levels of CD8+ were significantly increased. The levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were significantly increased, and the levels of CD8+ were significantly decreased. The levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group, and the levels of CD8+ were significantly lower than those in the control group (P<0.05). The scores of appetite, pain, fatigue, dyspnea, bloody sputum and cough in the two groups after treatment were significantly lower than those before treatment, and the above indexes in the observation group were significantly lower than those in the control group (P<0.05). The incidence of neutropenia and constipation in the observation group was significantly lower than that in the control group (P<0.05), and there was no statistical difference in the incidence of thrombocytopenia, nausea and vomiting and neurotoxicity between the two groups (P>0.05). Conclusion: Shenfu injection combined with docetaxel can significantly improve the immune function and quality of life of patients with advanced non-small cell lung cancer, improve the clinical treatment effect, and have high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
